SEPN NASDAQ
Credit Risk of going bust: lower than 71% of companies Debt: 1.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.07 (down 99.9%), Septerna Inc would be worth roughly what it owes.
Total debt $22.5M against a stock market value of $1.93B.
Distance to default 7.72 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $11.3M (short-term plus half of long-term), stock volatility 64.9%; Altman Z'' 4.35. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
South San Francisco, CA 94080
US
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for gravesâ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, womenâs health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bhatt Elizabeth | S-Sale | 1,094 | $36.87 | 2026-10-15 |
| Bhatt Elizabeth | S-Sale | 2,906 | $37.61 | 2026-10-15 |
| Patni Rajiv | A-Award | 275,000 | $37.37 | 2026-09-08 |
| Long Daniel D. | S-Sale | 3,333 | $37.83 | 2026-09-01 |
| Patni Rajiv | 0 | — | 2026-08-24 |